This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.
efficacy against Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory CLL or SLL, as well as against bendamustine plus rituximab in treatment-naïve CLL or SLL patients.
The Janssen Pharmaceutical Companies of Johnson &Johnson (Janssen) have shared results from a real-world study evaluating the use of Imbruvica (ibrutinib) in patients with chronic lymphocytic leukaemia (CLL). ... medical affairs, oncology, Janssen Biotech
Astex subsequently entered into a drug discovery collaboration and licence agreement on FGFR inhibitors with Janssen – a pharmaceutical arm of Johnson &Johnson – which resulted in the identification of Balversa (erdafitinib), approved
The company recently presented positive results from a phase 3b study which showed the combination of cabotegravir with Janssen’s – a pharmaceutical arm of Johnson &Johnson – Rekambys (rilpivirine long-acting injectable
Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Tecvayli (teclistamab-cqyv) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with ... We are greatly encouraged by the FDA’s
The combination therapy significantly improved progression-free and overall survival rates. Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Erleada (apalutamide), in combination with androgen deprivation therapy (ADT),
More from news
Approximately 158 fully matching, plus 423 partially matching documents found.
Jennifer Lee is Therapy Area Market Access Leader for Janssen EMEA.
Personalisation was also cited as one of three key trends shaping the future of our industry, along with commercial excellence and flexibility, by Janssen’s Maria Raad, Janssen EMEA’s vice
3. Janssen, as part of the pharmaceutical companies of Johnson &Johnson, has a 130-year heritage in healthcare. ... When it comes to decision-making in dermatological R&D, Janssen works with patients to enshrine the patient voice.
It’s exactly how we are at Janssen now, and I am thankful to have a team dedicated to driving the science forwards. ... Neil Davie is Head of Late Development, Cardiovascular, Metabolism &Pulmonary Hypertension at the Janssen Pharmaceutical Companies
Lee-Ann Farrell comments: “I’m committed to championing all DE&I efforts throughout Janssen. ... References are available on request. This article has been commissioned by, and developed by, Janssen-Cilag Ltd.
More from intelligence
Approximately 5 fully matching, plus 59 partially matching documents found.
Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson &Johnson and Janssen.
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.
Our first confirmed speaker is Daniel de Schryver, Patient Engagement &Advocacy Lead, Europe, Middle-East and Africa, Janssen.
Copywriting. AKLRD | A Life in a Day | Allergan | Amgen | Arquer Diagnostics | Bleepa | Boehringer Ingelheim | Galapagos | Inivata | Janssen | Kantar | Maxwellia | Macmillan | Mundipharma | Norgine | Novo Nordisk | Pfizer | Roche | Sanofi | Santen |
Working with global pharma clients such as Takeda, GSK, Janssen and Abbvie, the consultancy is on a trajectory for growth and has doubled in size due to its commitment to technology,
Recently, Darzalex (daratumumab), a monoclonal antibody developed by Genmab and Janssen, that has been available for the management of patients with multiple myeloma across Europe for 5 years, was granted accelerated
READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:. The Immunology Training Summit (ITS) 2020 with the Janssen EMEA Immunology team took a week-long face-to-face meeting for ... Strikingly this format is now considered best practice in
More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.
Accession was a born from a passion and a vision. A passion to harness the power of market access to...